Gene · 140
ADORA3: adenosine A3 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADORA3: adenosine A3 receptor. Genes, record 140. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/140
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P0DMS8 | Adenosine receptor A3 | 318 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36625 | P0DMS8 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2684 | P0DMS8 | Espacenet |
| US 11673938 B2 | 2023-06-13 | 7 | P0DMS8 | Espacenet |
| US 11584923 B2 | 2023-02-21 | 537 | P0DMS8 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 2684 | P0DMS8 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 192 | P0DMS8 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 105655 | P0DMS8 | Espacenet |
| US 10772934 B2 | 2020-09-15 | 978 | P0DMS8 | Espacenet |
| US 10292374 B2 | 2019-05-21 | 264 | P0DMS8 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 217060 | P0DMS8 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs12
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADENOSINE | CHEMBL477 | Adenosine receptor agonist | AGONIST | ChEMBL |
| AMINOPHYLLINE | CHEMBL1370561 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAFFEINE | CHEMBL113 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAFFEINE CITRATE | CHEMBL1200569 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| NAMODENOSON | CHEMBL431733 | Adenosine A3 receptor agonist | AGONIST | ChEMBL |
| OXTRIPHYLLINE | CHEMBL1200434 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| PICLIDENOSON | CHEMBL3989873 | Adenosine A3 receptor agonist | AGONIST | ChEMBL |
| QAF805 | CHEMBL3545204 | Adenosine A3 receptor antagonist | ANTAGONIST | ChEMBL |
| THEOPHYLLINE | CHEMBL1355736 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| THEOPHYLLINE ANHYDROUS | CHEMBL190 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 12
See all 12 drugsTrials172
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07469852 | CAFFEINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07466732 | CAFFEINE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07456670 | CAFFEINE | PHASE2 | ClinicalTrials.gov | |
| NCT07410455 | PICLIDENOSON | PHASE2 | ClinicalTrials.gov | |
| NCT07348510 | AMINOPHYLLINE | ClinicalTrials.gov | ||
| NCT07262060 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07216365 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07086560 | ADENOSINE | ClinicalTrials.gov | ||
| NCT06972849 | CAFFEINE CITRATE | ClinicalTrials.gov | ||
| NCT06972108 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 172
See all 172 trialsNIH grants933
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADORA3 papers | Newest fiscal year |
|---|---|---|---|
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 132 | 2025 |
| ZIADK031126 | Computer Modeling of G Protein-Coupled Receptors | 37 | 2025 |
| ZIADK031115 | Functionalized Congeners of Bioactive Compounds | 27 | 2025 |
| ZIADK031116 | Development of P2Y Receptor Ligands | 13 | 2025 |
| P30DK056338 | Texas Medical Center Digestive Diseases Center | 3 | 2025 |
| P30EY001583 | P30 Core Grant For Vision Research | 3 | 2025 |
| R01HL155950 | Targeting Myeloid Dependent MicroRNAs in Acute Respiratory Distress Syndrome | 3 | 2025 |
| R35GM128840 | Discovering and Exploiting Selectivity within Tandem Bromodomains | 3 | 2025 |
| ZIAAA000375 | Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injury | 3 | 2025 |
| ZIADK031127 | Development of Drugs Acting at Ion Channels | 3 | 2025 |
1 to 10 of 933Source NIH's project files
See all 933 nih grantsPapers1,628
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cannabinoids as context-dependent modulators of the adenosine A3 receptors: Potential orthosteric and allosteric mechanisms. | Pharmacol Res | 2026 | 42785538 | PubTator, text mining | PubMed |
| Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes. | J Biol Chem | 2026 | 42660457 | PubTator, text mining | PubMed |
| Correction: Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury. | J Neuroinflammation | 2026 | 42608691 | PubTator, text mining | PubMed |
| 4'-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective. | Med Chem Res | 2026 | 42446536 | PubTator, text mining | PubMed |
| From empirical screening to lipid trolling: the evolution of extrahelical allosteric modulators of A1 and A3 adenosine receptors. | Med Chem Res | 2026 | 42446533 | PubTator, text mining | PubMed |
| Neuropathic pain in traumatic brain injury: consequences, mechanisms, and therapeutic avenues. | Inflammopharmacology | 2026 | 42406251 | PubTator, text mining | PubMed |
| A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation. | Biomolecules | 2026 | 42352373 | PubTator, text mining | PubMed |
| Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study. | Sci Rep | 2026 | 42265358 | PubTator, text mining | PubMed |
| Expression of adenosine A1, A2A, A2B, and A3 receptors in ovarian cancer: their clinical potential in diagnosis and prognosis. | Mol Biol Rep | 2026 | 42234312 | PubTator, text mining | PubMed |
| Adenosine receptors in blood cells: Biomarkers and beyond. | Pharmacol Res | 2026 | 42219091 | PubTator, text mining | PubMed |
1 to 10 of 1,628
See all 1,628 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/140
GET https://conductscience.org/api/genes/v1/140/patents?page=2